Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in Clin Lung Cancer

Retrieve available abstracts of 207 articles:
HTML format



Single Articles


    September 2021
  1. TU HY, Li YS, Bai XY, Sun YL, et al
    Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
    Clin Lung Cancer. 2021 Sep 20. pii: S1525-7304(21)00242.
    PubMed     Abstract available


  2. SAKAGUCHI T, Kokubo Y, Furuhashi K, Nakamura Y, et al
    An Extensive-stage Small-cell Lung Cancer Case With Preexisting Lambert-Eaton Myasthenic Syndrome Successfully Treated With an Immune Checkpoint Inhibitor.
    Clin Lung Cancer. 2021 Sep 17. pii: S1525-7304(21)00241.
    PubMed    


    August 2021
  3. MYNARD N, Saxena A, Mavracick A, Port J, et al
    Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report.
    Clin Lung Cancer. 2021 Aug 29. pii: S1525-7304(21)00214.
    PubMed     Abstract available


  4. JIN Y, Xue Q, Shen X, Zheng Q, et al
    PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort.
    Clin Lung Cancer. 2021 Aug 28. pii: S1525-7304(21)00213.
    PubMed     Abstract available


  5. SEITLINGER J, Prieto M, Guerrera F, Streit A, et al
    Neutrophil-to-lymphocyte ratio is correlated to driver gene mutations in surgically-resected non-small cell lung cancer and its post-operative evolution impacts outcomes.
    Clin Lung Cancer. 2021 Aug 22. pii: S1525-7304(21)00205.
    PubMed     Abstract available


  6. WOODARD GA, Kratz JR, Haro G, Gubens MA, et al
    Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
    Clin Lung Cancer. 2021 Aug 20. pii: S1525-7304(21)00212.
    PubMed     Abstract available


  7. TAKADA K, Takamori S, Miura N, Shikada Y, et al
    Comments on 'The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors'.
    Clin Lung Cancer. 2021 Aug 10. pii: S1525-7304(21)00208.
    PubMed    


  8. LEE M, Patel D, Jofre S, Fidvi S, et al
    Large Cell Neuroendocrine Carcinoma Transformation as a Mechanism of Acquired Resistance to Osimertinib in Non-small Cell Lung Cancer: Case Report and Literature Review.
    Clin Lung Cancer. 2021 Aug 10. pii: S1525-7304(21)00206.
    PubMed    


    July 2021
  9. LI X, Chen X, He S, Chen H, et al
    The Application of Pigtail Catheters in Postoperative Drainage of Lung Cancer.
    Clin Lung Cancer. 2021 Jul 31. pii: S1525-7304(21)00191.
    PubMed     Abstract available


  10. REUSS JE, Gosa L, Liu SV
    Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.
    Clin Lung Cancer. 2021 Jul 25. pii: S1525-7304(21)00192.
    PubMed     Abstract available


  11. GJYSHI O, Lin SH, Pezzi TA, Ning MS, et al
    Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases.
    Clin Lung Cancer. 2021 Jul 24. pii: S1525-7304(21)00184.
    PubMed     Abstract available


  12. UMEMURA S, Chen V, Chahine JJ, Kallakury B, et al
    Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Jul 20. pii: S1525-7304(21)00187.
    PubMed     Abstract available


  13. WONG DJ, Bauer TM, Gordon MS, Bene-Tchaleu F, et al
    Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial.
    Clin Lung Cancer. 2021 Jul 20. pii: S1525-7304(21)00183.
    PubMed     Abstract available


  14. SINGH S, Pavesi F, Steiling K, Asokan S, et al
    Risk Factors for Lung Cancer in an Underrepresented Safety-Net Screening Cohort.
    Clin Lung Cancer. 2021 Jul 19. pii: S1525-7304(21)00190.
    PubMed     Abstract available


  15. DE RUYSSCHER D, Ramalingam S, Urbanic J, Gerber DE, et al
    CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-S
    Clin Lung Cancer. 2021 Jul 19. pii: S1525-7304(21)00186.
    PubMed     Abstract available


  16. TAKAMORI S, Takada K, Shimokawa M, Okamoto T, et al
    Comments on "Lobe-specific Lymph Node Dissection in Clinical Stage IA Solid-dominant Non-small-cell Lung Cancer: A Propensity Score Matching Study".
    Clin Lung Cancer. 2021 Jul 7. pii: S1525-7304(21)00181.
    PubMed    


  17. MANGLAVITI S, Brambilla M, Signorelli D, Ferrara R, et al
    Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
    Clin Lung Cancer. 2021 Jul 5. pii: S1525-7304(21)00180.
    PubMed     Abstract available


  18. KOOPMAN B, Groen HJM, Schuuring E, Hiltermann TJN, et al
    Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.
    Clin Lung Cancer. 2021 Jul 3. pii: S1525-7304(21)00178.
    PubMed     Abstract available


  19. TSUI DCC, Aisner D, Nijmeh H, Bao L, et al
    Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy.
    Clin Lung Cancer. 2021 Jul 3. pii: S1525-7304(21)00179.
    PubMed    


    June 2021
  20. YU HA, Goldberg SB, Le X, Piotrowska Z, et al
    Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).
    Clin Lung Cancer. 2021 Jun 25. pii: S1525-7304(21)00157.
    PubMed     Abstract available


  21. YANG Y, Deng L, Yang Y, Zhang T, et al
    Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2021 Jun 24. pii: S1525-7304(21)00160.
    PubMed     Abstract available


  22. JACOBS CD, Mehta K, Gao J, Wang X, et al
    Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Jun 24. pii: S1525-7304(21)00159.
    PubMed     Abstract available


  23. BARTA JA, Shusted CS, Ruane B, Pimpinelli M, et al
    Racial Differences in Lung Cancer Screening Beliefs and Screening Adherence.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00143.
    PubMed     Abstract available


  24. SAITO G, Kono M, Koyanagi Y, Miyashita K, et al
    Significance of Brain Imaging for Staging in Patients With Clinical Stage T1-2 N0 Non-Small-Cell Lung Cancer on Positron Emission Tomography/Computed Tomography.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00145.
    PubMed     Abstract available


  25. PINQUIE F, Cortot AB, Chevalier LM, Morel A, et al
    A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00142.
    PubMed    


  26. TSUI DCC, Kavanagh BD, Honce JM, Rossi C, et al
    Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib.
    Clin Lung Cancer. 2021 Jun 12. pii: S1525-7304(21)00148.
    PubMed    


  27. HENDRIKS LEL, Remon J, Besse B
    Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 Expression.
    Clin Lung Cancer. 2021 Jun 12. pii: S1525-7304(21)00149.
    PubMed    


  28. SOCINSKI MA, Ozguroglu M, Villegas A, Daniel D, et al
    Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
    Clin Lung Cancer. 2021 Jun 12. pii: S1525-7304(21)00144.
    PubMed     Abstract available


    May 2021
  29. GADGEEL S, Hirsch FR, Kerr K, Barlesi F, et al
    Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
    Clin Lung Cancer. 2021 May 30. pii: S1525-7304(21)00101.
    PubMed     Abstract available


  30. LI Y, Zhang Y, Jia X, Jiang P, et al
    Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non-Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis.
    Clin Lung Cancer. 2021 May 28. pii: S1525-7304(21)00098.
    PubMed     Abstract available


  31. LEAL JL, Alexander M, Itchins M, Wright GM, et al
    EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 May 16. pii: S1525-7304(21)00093.
    PubMed     Abstract available


  32. RIESS JW, Reckamp KL, Frankel P, Longmate J, et al
    Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).
    Clin Lung Cancer. 2021 May 15. pii: S1525-7304(21)00094.
    PubMed     Abstract available


    April 2021
  33. HAMADA A, Soh J, Hata A, Nakamatsu K, et al
    Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L).
    Clin Lung Cancer. 2021 Apr 27. pii: S1525-7304(21)00090.
    PubMed     Abstract available


  34. OYANAGI J, Koh Y, Sato K, Teraoka S, et al
    Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
    Clin Lung Cancer. 2021 Apr 27. pii: S1525-7304(21)00091.
    PubMed     Abstract available


  35. BYERS LA, Navarro A, Schaefer E, Johnson M, et al
    A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Apr 24. pii: S1525-7304(21)00089.
    PubMed     Abstract available


  36. FISHER A, Kim S, Farhat D, Belzer K, et al
    Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer.
    Clin Lung Cancer. 2021 Apr 23. pii: S1525-7304(21)00088.
    PubMed     Abstract available


  37. MERKHOFER CM, Eaton KD, Martins RG, Ramsey SD, et al
    Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Apr 22. pii: S1525-7304(21)00087.
    PubMed     Abstract available


  38. RAEZ LE, Carracedo C, Drusbosky LM, Velez M, et al
    EGFR L718V (+)/T790M (-) as a Mechanism of Resistance in Patients with Metastatic Non-small-cell Lung Cancer with EGFR L858R Mutations.
    Clin Lung Cancer. 2021 Apr 9. pii: S1525-7304(21)00072.
    PubMed    


    March 2021
  39. MORAN A, Wang Y, Dyer BA, Yip SSF, et al
    Prognostic Value of Computed Tomography and/or (18)F-Fluorodeoxyglucose Positron Emission Tomography Radiomics Features in Locally Advanced Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Mar 27. pii: S1525-7304(21)00069.
    PubMed     Abstract available


  40. ARRIETA O, Varela-Santoyo E, Cardona AF, Sanchez-Reyes R, et al
    Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2021 Mar 27. pii: S1525-7304(21)00068.
    PubMed     Abstract available


  41. KAO C, Powers E, Wu Y, Datto MB, et al
    Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2021 Mar 27. pii: S1525-7304(21)00071.
    PubMed     Abstract available


  42. SHEN Q, Kalyani FS, Qu J, Chen Z, et al
    A Case of Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion with Partial Response to Crizotinib.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00066.
    PubMed    


  43. WEISS J, Goldschmidt J, Andric Z, Dragnev KH, et al
    Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00064.
    PubMed     Abstract available


  44. BRAINSON CF, Huang B, Chen Q, McLouth LE, et al
    Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian Kentucky.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00061.
    PubMed     Abstract available


  45. KELLER A, Ghanta S, Rodriguez-Lopez JL, Patel A, et al
    Utility of Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer in the MRI Screening Era.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00063.
    PubMed     Abstract available


  46. CABEZON-GUTIERREZ L, Custodio-Cabello S, Palka-Kotlowska M, Alonso-Viteri S, et al
    Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1.
    Clin Lung Cancer. 2021 Mar 24. pii: S1525-7304(21)00060.
    PubMed     Abstract available


  47. DALL'OLIO FG, Gelsomino F, Conci N, Marcolin L, et al
    PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2021 Mar 16. pii: S1525-7304(21)00057.
    PubMed     Abstract available


    February 2021
  48. SATOH H, Miyazaki K, Kagohashi K
    Letter to the Editor Regarding "Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy".
    Clin Lung Cancer. 2021 Feb 27. pii: S1525-7304(21)00051.
    PubMed    


  49. GREGORC V, Mazzarella L, Lazzari C, Graziano P, et al
    Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Feb 25. pii: S1525-7304(20)30350.
    PubMed     Abstract available


  50. KIKUCHI Y, Nakatani Y, Yamaguchi T
    Where Is the Primary Site of the Extra-Axial Chordoma Masquerading As Lung Cancer?
    Clin Lung Cancer. 2021 Feb 24. pii: S1525-7304(21)00047.
    PubMed    


  51. BALL S, Dash A, Igid HP, Thein KZ, et al
    Extra-axial Chordoma Masquerading as Lung Cancer.
    Clin Lung Cancer. 2021 Feb 23. pii: S1525-7304(21)00048.
    PubMed    


  52. ARGIRIS A, Miao J, Cristea MC, Chen AM, et al
    A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811).
    Clin Lung Cancer. 2021 Feb 19. pii: S1525-7304(21)00032.
    PubMed     Abstract available


  53. GARON EB, Cho BC, Reinmuth N, Lee KH, et al
    Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
    Clin Lung Cancer. 2021 Feb 19. pii: S1525-7304(21)00033.
    PubMed     Abstract available


  54. KOGURE Y, Hashimoto H, Oki M
    A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol.
    Clin Lung Cancer. 2021 Feb 19. pii: S1525-7304(21)00031.
    PubMed     Abstract available


  55. PENG L, Deng HY, Yang Y
    Lobe-specific Lymph Node Dissection for Clinical Stage IA Non-small-cell Lung Cancer: What do we know?
    Clin Lung Cancer. 2021 Feb 16. pii: S1525-7304(21)00030.
    PubMed    


  56. BOYCE-FAPPIANO D, Nguyen QN, Chapman BV, Allen PK, et al
    Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2021 Feb 7. pii: S1525-7304(21)00025.
    PubMed     Abstract available


  57. LIN X, Jiao H, Pang Z, Chen H, et al
    Lung Cancer and Granuloma Identification Using a Deep Learning Model to Extract 3-Dimensional Radiomics Features in CT Imaging.
    Clin Lung Cancer. 2021 Feb 6. pii: S1525-7304(21)00027.
    PubMed     Abstract available


  58. FERRARA MG, Martini M, D'Argento E, Forcella C, et al
    PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
    Clin Lung Cancer. 2021 Feb 5. pii: S1525-7304(20)30351.
    PubMed     Abstract available


  59. GOULART BHL, Chennupati S, Fedorenko CR, Ramsey SD, et al
    Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR(+) and ALK(+) Positive Non-small-cell Lung Cancer Treated in the Real-World.
    Clin Lung Cancer. 2021 Feb 4. pii: S1525-7304(21)00022.
    PubMed     Abstract available


  60. SHINTANI T, Kishi N, Matsuo Y, Ogura M, et al
    Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non-Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab.
    Clin Lung Cancer. 2021 Feb 4. pii: S1525-7304(21)00020.
    PubMed     Abstract available


  61. LI GJ, Tan H, Chen H, Parmar A, et al
    Immunotherapy and Stereotactic Ablative Radiotherapy for Lung Cancer with Co-existing Interstitial Lung Disease: A Case Report.
    Clin Lung Cancer. 2021 Feb 4. pii: S1525-7304(21)00021.
    PubMed    


  62. KIRKLAND RS, Kole AJ, Batra H, Boggs DH, et al
    Predictors of In-Hospital Death in Patients with Lung Cancer Admitted for Acute Radiation Pneumonitis: A Healthcare Cost and Utilization Project (HCUP) Analysis.
    Clin Lung Cancer. 2021 Feb 3. pii: S1525-7304(21)00019.
    PubMed     Abstract available


    January 2021
  63. KERRIGAN K, Wang X, Haaland B, Adamson B, et al
    Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status.
    Clin Lung Cancer. 2021 Jan 26. pii: S1525-7304(21)00016.
    PubMed     Abstract available


  64. MATTES MD, Eubank TD, Almubarak M, Wen S, et al
    A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Jan 25. pii: S1525-7304(21)00015.
    PubMed     Abstract available


  65. SHUKLA NA, Althouse S, Meyer Z, Hanna N, et al
    Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Jan 23. pii: S1525-7304(21)00002.
    PubMed     Abstract available


  66. MERRITT RE, Abdel-Rasoul M, D'Souza DM, Kneuertz PJ, et al
    Racial Disparities in Overall Survival and Surgical Treatment for Early Stage Lung Cancer by Facility Type.
    Clin Lung Cancer. 2021 Jan 22. pii: S1525-7304(21)00010.
    PubMed     Abstract available


  67. KEISER MF, Patel AB, Altan M
    Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
    Clin Lung Cancer. 2021 Jan 22. pii: S1525-7304(21)00009.
    PubMed     Abstract available


  68. LIU J, Hui C, Ladbury C, Waddington T, et al
    Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy.
    Clin Lung Cancer. 2021 Jan 19. pii: S1525-7304(21)00006.
    PubMed     Abstract available


  69. OWONIKOKO TK, Redman MW, Byers LA, Hirsch FR, et al
    Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.
    Clin Lung Cancer. 2021 Jan 10. pii: S1525-7304(21)00004.
    PubMed     Abstract available


  70. CHAN SWS, Smith E, Aggarwal R, Balaratnam K, et al
    Systemic Inflammatory Markers of Survival in Epidermal Growth Factor-Mutated Non-Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis.
    Clin Lung Cancer. 2021 Jan 10. pii: S1525-7304(21)00005.
    PubMed     Abstract available


  71. LU S, Casarini I, Kato T, Cobo M, et al
    Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.
    Clin Lung Cancer. 2021 Jan 6. pii: S1525-7304(20)30337.
    PubMed     Abstract available


  72. AL-AHMADI A, Ardeshir-Larijani F, Fu P, Cao S, et al
    Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival.
    Clin Lung Cancer. 2021;22:16-22.
    PubMed     Abstract available


    December 2020
  73. KAMIGAICHI A, Tsutani Y, Mimae T, Miyata Y, et al
    Prediction of Unexpected N2 Disease Associated With Clinical T1-2N0-1M0 Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Dec 27. pii: S1525-7304(20)30364.
    PubMed     Abstract available


  74. YAMAMOTO N, Harada H, Okamoto I, Masuda N, et al
    Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Dec 26. pii: S1525-7304(20)30366.
    PubMed     Abstract available


  75. MALLER B, Simmons VN, Byrne MM, Tanvetyanon T, et al
    Characteristics and Outcomes of Lung Cancer Screening Among Individuals With or Without Cancer History.
    Clin Lung Cancer. 2020 Dec 19. pii: S1525-7304(20)30349.
    PubMed     Abstract available


  76. WANG X, Jiang S, You X, Aramini B, et al
    Extended Sleeve Lobectomy is an Alternative for Centrally Located Lung Cancer With Superior Short- and Long-term Outcomes.
    Clin Lung Cancer. 2020 Dec 17. pii: S1525-7304(20)30345.
    PubMed     Abstract available


  77. RAZ DJ, Ismail MH, Haupt EC, Sun V, et al
    Improving Utilization of Lung Cancer Screening Through Incorporating a Video-Based Educational Tool Into Smoking Cessation Counseling.
    Clin Lung Cancer. 2020 Dec 15. pii: S1525-7304(20)30346.
    PubMed     Abstract available


  78. GERBER DE, Hamann HA, Dorsey O, Ahn C, et al
    Clinician Variation in Ordering and Completion of Low-Dose Computed Tomography for Lung Cancer Screening in a Safety-Net Medical System.
    Clin Lung Cancer. 2020 Dec 11. pii: S1525-7304(20)30344.
    PubMed     Abstract available


  79. BUSTAMANTE ALVAREZ JG, Janse S, Owen DH, Kiourtsis S, et al
    Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Clin Lung Cancer. 2020 Dec 2. pii: S1525-7304(20)30340.
    PubMed     Abstract available


  80. HYSELL K, Yusuf R, Barakat L, Virata M, et al
    Decreased Overall Survival in HIV-associated Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Dec 2. pii: S1525-7304(20)30339.
    PubMed     Abstract available


  81. METZENMACHER M, Goetz M, Herold T, Stuschke M, et al
    Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V(600)-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations.
    Clin Lung Cancer. 2020 Dec 2. pii: S1525-7304(20)30341.
    PubMed    


    November 2020
  82. LI T, Pan K, Ellinwood AK, Cress RD, et al
    Survival Trends of Metastatic Lung Cancer in California by Age at Diagnosis, Gender, Race/Ethnicity, and Histology, 1990-2014.
    Clin Lung Cancer. 2020 Nov 24. pii: S1525-7304(20)30338.
    PubMed     Abstract available


  83. YIN W, Cheng J, Tang Z, Toruner G, et al
    MET Amplification (MET/CEP7 Ratio >/= 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non-Small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Nov 17. pii: S1525-7304(20)30335.
    PubMed     Abstract available


  84. HANDA Y, Tsutani Y, Mimae T, Miyata Y, et al
    Surgical Procedure Selection for Stage I Lung Cancer: Complex Segmentectomy versus Wedge Resection.
    Clin Lung Cancer. 2020 Nov 17. pii: S1525-7304(20)30331.
    PubMed     Abstract available


  85. LI XM, Li WF, Lin JT, Yan HH, et al
    Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).
    Clin Lung Cancer. 2020 Nov 17. pii: S1525-7304(20)30334.
    PubMed     Abstract available


  86. BALASUBRAMANIAN A, Onggo J, Gunjur A, John T, et al
    Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results.
    Clin Lung Cancer. 2020 Nov 12. pii: S1525-7304(20)30333.
    PubMed     Abstract available


  87. SUN L, Davis CW, Hwang WT, Jeffries S, et al
    Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.
    Clin Lung Cancer. 2020 Nov 11. pii: S1525-7304(20)30327.
    PubMed     Abstract available


  88. ENRIGHT TL, Witt JS, Burr AR, Yadav P, et al
    Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
    Clin Lung Cancer. 2020 Nov 10. pii: S1525-7304(20)30324.
    PubMed     Abstract available


  89. BORGHAEI H, Redman MW, Kelly K, Waqar SN, et al
    SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study).
    Clin Lung Cancer. 2020 Nov 10. pii: S1525-7304(20)30325.
    PubMed     Abstract available


  90. NIE Y, Wang X, Yang F, Zhou Z, et al
    Surgical Prognosis of Synchronous Multiple Primary Lung Cancer: Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2020 Nov 5. pii: S1525-7304(20)30332.
    PubMed     Abstract available


  91. OWEN DH, Benner B, Pilcher C, Good L, et al
    Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells.
    Clin Lung Cancer. 2020 Nov 2. pii: S1525-7304(20)30328.
    PubMed    


    October 2020
  92. HARATAKE N, Seto T
    NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy.
    Clin Lung Cancer. 2020 Oct 24. pii: S1525-7304(20)30315.
    PubMed     Abstract available


  93. MERRITT RE, Abdel-Rasoul M, Fitzgerald M, D'Souza DM, et al
    Nomograms for Predicting Overall and Recurrence-free Survival From Pathologic Stage IA and IB Lung Cancer After Lobectomy.
    Clin Lung Cancer. 2020 Oct 22. pii: S1525-7304(20)30311.
    PubMed     Abstract available


  94. GARRANA SH, Dagogo-Jack I, Cobb R, Kuo AH, et al
    Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients.
    Clin Lung Cancer. 2020 Oct 21. pii: S1525-7304(20)30314.
    PubMed     Abstract available


  95. MA J, Pi G, Bi J, Li Y, et al
    Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non-small-cell Lung Cancer: Study Protocol for an Open-label Randomized Controlled Trial.
    Clin Lung Cancer. 2020 Oct 21. pii: S1525-7304(20)30309.
    PubMed     Abstract available


  96. RIUDAVETS M, Caramella C, Pradere P, Naltet C, et al
    Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non-small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report.
    Clin Lung Cancer. 2020 Oct 21. pii: S1525-7304(20)30313.
    PubMed    


  97. MELE MC, Rinninella E, Cintoni M, Pulcini G, et al
    Nutritional Support in Lung Cancer Patients: The State of the Art.
    Clin Lung Cancer. 2020 Oct 21. pii: S1525-7304(20)30310.
    PubMed     Abstract available


  98. ASAHINA H, Tanaka K, Morita S, Maemondo M, et al
    A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
    Clin Lung Cancer. 2020 Oct 16. pii: S1525-7304(20)30305.
    PubMed     Abstract available


  99. FRIIS RB, Hjollund NH, Pappot H, Taarnhoj GA, et al
    Patient-Reported Outcome Measures Used in Routine Care Predict for Survival at Disease Progression in Patients With Advanced Lung Cancer.
    Clin Lung Cancer. 2020 Oct 15. pii: S1525-7304(20)30294.
    PubMed     Abstract available


  100. SHAH AT, Bernardo RJ, Berry GJ, Kudelko K, et al
    Two Cases of Pulmonary Tumor Thrombotic Microangiopathy Associated with ROS1-Rearranged Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Oct 15. pii: S1525-7304(20)30302.
    PubMed    


  101. YU H, Brustugun OT, Ekman S, Botling J, et al
    Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2020 Oct 15. pii: S1525-7304(20)30299.
    PubMed     Abstract available


  102. ZHAO Y, Mao Y, He J, Gao S, et al
    Lobe-specific Lymph Node Dissection in Clinical Stage IA Solid-dominant Non-small-cell Lung Cancer: A Propensity Score Matching Study.
    Clin Lung Cancer. 2020 Oct 15. pii: S1525-7304(20)30291.
    PubMed     Abstract available


  103. TANAKA H, Hasegawa Y, Makiguchi T, Okumura F, et al
    A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Oct 14. pii: S1525-7304(20)30296.
    PubMed     Abstract available


  104. ZHANG J, Liu L, Wang G, Li S, et al
    Skip N2 Metastasis Shows Similar Prognosis to N1 Disease in Lung Cancer: Mechanism Discussion.
    Clin Lung Cancer. 2020 Oct 14. pii: S1525-7304(20)30306.
    PubMed    


  105. HE Z, Li Z, Xu S, Wu W, et al
    Prognostic Significance of Lymph Node Count Removed at Sublobar Resection in Pathologic Stage IA Non-Small-cell Lung Cancer: A Population-Based Analysis.
    Clin Lung Cancer. 2020 Oct 14. pii: S1525-7304(20)30295.
    PubMed     Abstract available


  106. JANSEN AME, Sriram JD, Pluim D, Maas RJH, et al
    Therapeutic Exposure and Successful Response to Pembrolizumab in a Patient With Non-Small-Cell Lung Cancer Despite Significant Renal Loss Due to Paraneoplastic Nephrotic Syndrome.
    Clin Lung Cancer. 2020 Oct 14. pii: S1525-7304(20)30303.
    PubMed    


  107. WAQAR SN, Redman MW, Arnold SM, Hirsch FR, et al
    A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
    Clin Lung Cancer. 2020 Oct 14. pii: S1525-7304(20)30293.
    PubMed     Abstract available


  108. PARK M, Ho DY, Wakelee HA, Neal JW, et al
    Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Oct 13. pii: S1525-7304(20)30292.
    PubMed     Abstract available


    September 2020
  109. ZHU YJ, Qu X, Zhan DD, Chen HH, et al
    Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Sep 19. pii: S1525-7304(20)30264.
    PubMed     Abstract available


  110. CITARELLA F, Russano M, Galletti A, Vincenzi B, et al
    Multiple and Concomitant Molecular Findings in a Heavily Treated Patient With EGFR-positive Lung Cancer.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30262.
    PubMed    


  111. CUSHMAN TR, Jones B, Akhavan D, Rusthoven CG, et al
    The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30265.
    PubMed     Abstract available


  112. DENG Z, Qin Y, Liu Y, Zhang Y, et al
    Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30271.
    PubMed     Abstract available


  113. VAN DE WIEL M, Derijcke S, Galdermans D, Daenen M, et al
    Coping Strategy Influences Quality of Life in Patients With Advanced Lung Cancer by Mediating Mood.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30274.
    PubMed     Abstract available


  114. SPIGEL DR, Jotte RM, Aix SP, Gressot L, et al
    Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30270.
    PubMed     Abstract available


  115. EKEKE CN, Mitchell C, Schuchert M, Dhupar R, et al
    Early Distant Recurrence in Patients With Resected Stage I Lung Cancer: A Case Series of "Blast Metastasis".
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30263.
    PubMed     Abstract available


  116. GOWER A, Kim J, Spector K, Menashe D, et al
    Three Primary Tumors Including EGFR-mutated Non-Small Cell Lung Cancer as First Presentation in Patient With Li-Fraumeni Syndrome.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30267.
    PubMed    


  117. BOWMAN L, Tiu R, Smyth EN, Willard MD, et al
    Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30275.
    PubMed     Abstract available


  118. JAHANZEB M, Lin HM, Pan X, Yin Y, et al
    Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Sep 18. pii: S1525-7304(20)30268.
    PubMed     Abstract available


  119. PASSARO A, Spitaleri G, de Marinis F
    Reply.
    Clin Lung Cancer. 2020;21:e415-e416.
    PubMed    


  120. CALIMAN E, Petreni P, Brugia M, Antonuzzo L, et al
    In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations".
    Clin Lung Cancer. 2020;21:e363-e365.
    PubMed    


    August 2020
  121. BONOMI M, Maltese M, Brighenti M, Muri M, et al
    Tocilizumab for COVID-19 Pneumonia in a Patient With Non-Small-cell Lung Cancer Treated With Chemoimmunotherapy.
    Clin Lung Cancer. 2020 Aug 26. pii: S1525-7304(20)30254.
    PubMed    


  122. GOROSPE L, Ayala-Carbonero AM, Paredes-Rodriguez P, Munoz-Molina GM, et al
    Challenges in Management of Patients With Lung Cancer in Times of COVID-19: An Imaging Perspective.
    Clin Lung Cancer. 2020 Aug 25. pii: S1525-7304(20)30253.
    PubMed    


  123. SOOD S, Ganju R, Shen X, Napel MT, et al
    Ultra-central Thoracic Re-irradiation Using 10-fraction Stereotactic Body Radiotherapy for Recurrent Non-small-cell Lung Cancer Tumors: Preliminary Toxicity and Efficacy Outcomes.
    Clin Lung Cancer. 2020 Aug 11. pii: S1525-7304(20)30150.
    PubMed     Abstract available


  124. OH MS, Guzner A, Wainwright DA, Mohindra NA, et al
    The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2020 Aug 5. pii: S1525-7304(20)30238.
    PubMed     Abstract available


  125. CHIC N, Mezquita L, Aldea M, Chebib R, et al
    Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAF(V600E)-Mutant Metastatic Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Aug 5. pii: S1525-7304(20)30235.
    PubMed    


  126. PASSIGLIA F, Bironzo P, Righi L, Listi A, et al
    A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes:
    Clin Lung Cancer. 2020 Aug 5. pii: S1525-7304(20)30236.
    PubMed     Abstract available


    July 2020
  127. CHEN XR, Hou X, Li DL, Sai K, et al
    Management of Non-Small-Cell Lung Cancer Patients Initially Diagnosed With 1 to 3 Synchronous Brain-Only Metastases: A Retrospective Study.
    Clin Lung Cancer. 2020 Jul 30. pii: S1525-7304(20)30233.
    PubMed     Abstract available


  128. DARWIN A, Rose T, Tandon A, Tanvetyanon T, et al
    Development of Bronchopleural Fistula After Durvalumab Consolidation for Stage III Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Jul 30. pii: S1525-7304(20)30232.
    PubMed    


  129. MANKUZHY NP, Almahariq MF, Siddiqui ZA, Thompson AB, et al
    The Role of Postoperative Radiation Therapy for pN2 Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Jul 30. pii: S1525-7304(20)30230.
    PubMed     Abstract available


  130. HALL PE, Ready N, Johnston A, Bomalaski JS, et al
    Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Jul 30. pii: S1525-7304(20)30234.
    PubMed     Abstract available


  131. STENEHJEM DD, Lubinga SJ, Gupte-Singh K, Zhang Y, et al
    Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
    Clin Lung Cancer. 2020 Jul 29. pii: S1525-7304(20)30231.
    PubMed     Abstract available


  132. ZHENG J, Shen L, Jiang N, Zhu Y, et al
    First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Jul 9. pii: S1525-7304(20)30223.
    PubMed     Abstract available


  133. CHANG Q, Xu J, Qiang H, Teng J, et al
    EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.
    Clin Lung Cancer. 2020 Jul 6. pii: S1525-7304(20)30187.
    PubMed     Abstract available


  134. BLAKELY AM, Hu H, Wong FL, Raz DJ, et al
    Deterioration in Health-Related Quality of Life Diminishes Benefit of Lung Cancer Resection in Older Adults.
    Clin Lung Cancer. 2020 Jul 3. pii: S1525-7304(20)30216.
    PubMed     Abstract available


  135. SHEIKHBAHAEI S, Verde F, Hales RK, Rowe SP, et al
    Imaging in Therapy Response Assessment and Surveillance of Lung Cancer: Evidenced-based Review With Focus on the Utility of (18)F-FDG PET/CT.
    Clin Lung Cancer. 2020 Jul 3. pii: S1525-7304(20)30214.
    PubMed     Abstract available


  136. MERRITT RE, Kneuertz PJ
    Considerations for the Surgical Management of Early Stage Lung Cancer During the COVID-19 Pandemic.
    Clin Lung Cancer. 2020 Jul 3. pii: S1525-7304(20)30218.
    PubMed     Abstract available


  137. BOURHIS A, Remoue A, Uguen A
    KRAS and BRAF Double Mutations and Functional Classes of BRAF Mutations in Non-small-cell Lung Cancers.
    Clin Lung Cancer. 2020;21:e240-e242.
    PubMed    


    June 2020
  138. WONG W, Wu N, Gupta R, Mansfield AS, et al
    Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices.
    Clin Lung Cancer. 2020 Jun 29. pii: S1525-7304(20)30213.
    PubMed     Abstract available


  139. MIERAS A, Pasman HRW, Klop HT, Onwuteaka-Philipsen BD, et al
    What Goals Do Patients and Oncologists Have When Starting Medical Treatment for Metastatic Lung Cancer?
    Clin Lung Cancer. 2020 Jun 21. pii: S1525-7304(20)30208.
    PubMed     Abstract available


  140. RECKAMP KL, Patil T, Kirtane K, Rich TA, et al
    Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
    Clin Lung Cancer. 2020 Jun 20. pii: S1525-7304(20)30209.
    PubMed     Abstract available


  141. AUGUSTYN A, Adams DL, He J, Qiao Y, et al
    Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab.
    Clin Lung Cancer. 2020 Jun 20. pii: S1525-7304(20)30210.
    PubMed     Abstract available


  142. ZHAO Y, Zhai L, Deng L, Halmos B, et al
    Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature Review.
    Clin Lung Cancer. 2020 Jun 19. pii: S1525-7304(20)30211.
    PubMed    


  143. MULLER DA, Dutta SW, Aliotta E, Sanders JC, et al
    Clinical Outcomes and Predictors of Lung Toxicity After Multiple Courses of Lung Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2020 Jun 12. pii: S1525-7304(20)30188.
    PubMed     Abstract available


  144. PATEL JD, Lee JW, Carbone DP, Wagner H, et al
    Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
    Clin Lung Cancer. 2020 Jun 12. pii: S1525-7304(20)30189.
    PubMed     Abstract available


  145. COSTA GJ, Silva GTD, Ferreira CG, Mello MJG, et al
    Brazilian Women With Lung Cancer Have a Higher Overall Survival Than Their Male Equivalents: A Cohort Study.
    Clin Lung Cancer. 2020 Jun 6. pii: S1525-7304(20)30162.
    PubMed     Abstract available


  146. SEHGAL K, Bulumulle A, Brody H, Gill RR, et al
    Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Jun 5. pii: S1525-7304(20)30168.
    PubMed     Abstract available


  147. TSIMBERIDOU AM, Elkin S, Dumanois R, Pritchard D, et al
    Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Jun 5. pii: S1525-7304(20)30169.
    PubMed     Abstract available


  148. URBANSKA EM, Santoni-Rugiu E, Melchior LC, Carlsen JF, et al
    Intracranial Response of ALK(+) Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery.
    Clin Lung Cancer. 2020 Jun 4. pii: S1525-7304(20)30135.
    PubMed    


  149. GUERINI AE, Borghetti P, Filippi AR, Bonu ML, et al
    Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab.
    Clin Lung Cancer. 2020 Jun 2. pii: S1525-7304(20)30167.
    PubMed    


  150. SITTENFELD SMC, Juloori A, Reddy CA, Stephans KL, et al
    Salvage Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Primary Surgical Resection of Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 Jun 2. pii: S1525-7304(20)30165.
    PubMed     Abstract available


  151. UPRETY D, Borgert AJ, Fitzsimmons AJ, Parsons BM, et al
    External Validation of AJCC Eighth Edition of Non-small-cell Lung Cancer Staging Among African Americans.
    Clin Lung Cancer. 2020 Jun 2. pii: S1525-7304(20)30170.
    PubMed     Abstract available


  152. ELBANNA M, Shiue K, Edwards D, Cerra-Franco A, et al
    Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
    Clin Lung Cancer. 2020 Jun 2. pii: S1525-7304(20)30164.
    PubMed     Abstract available


    May 2020
  153. BYLICKI O, Riviere F, Tournier C, Canoui-Poitrine F, et al
    Factors Associated With Aggressiveness of End-of-Life Care for Lung Cancer Patients and Associated Costs of Care.
    Clin Lung Cancer. 2020 May 23. pii: S1525-7304(20)30157.
    PubMed     Abstract available


  154. HIRSCH EA, New ML, Brown SL, Baron AE, et al
    Impact of a Hybrid Lung Cancer Screening Model on Patient Outcomes and Provider Behavior.
    Clin Lung Cancer. 2020 May 23. pii: S1525-7304(20)30158.
    PubMed     Abstract available


  155. FRIEDES C, Mai N, Hazell S, Fu W, et al
    Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection With a Prediction Nomogram.
    Clin Lung Cancer. 2020 May 23. pii: S1525-7304(20)30153.
    PubMed     Abstract available


  156. GIJTENBEEK RGP, Damhuis RAM, Groen HJM, van der Wekken AJ, et al
    Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2020 May 22. pii: S1525-7304(20)30159.
    PubMed     Abstract available


  157. MIURA S, Yamanaka T, Kato T, Ikeda S, et al
    Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834).
    Clin Lung Cancer. 2020 May 21. pii: S1525-7304(20)30151.
    PubMed     Abstract available


  158. ENDOH H, Yamamoto R, Ichikawa A, Shiozawa S, et al
    Clinicopathologic Significance of False-Positive Lymph Node Status on FDG-PET in Lung Cancer.
    Clin Lung Cancer. 2020 May 14. pii: S1525-7304(20)30142.
    PubMed     Abstract available


  159. LUCIANI A, Marra A, Toschi L, Cortinovis D, et al
    Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged >/= 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
    Clin Lung Cancer. 2020 May 13. pii: S1525-7304(20)30144.
    PubMed     Abstract available


  160. CHIANG AC, Sequist LVD, Gilbert J, Conkling P, et al
    Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 May 12. pii: S1525-7304(20)30148.
    PubMed     Abstract available


  161. BALL S, Dash A, Igid HP, Thein KZ, et al
    Primary Extra-axial Chordoma Masquerading as Lung Cancer: Case Report and Review of the Literature.
    Clin Lung Cancer. 2020 May 11. pii: S1525-7304(20)30141.
    PubMed    


  162. GOBBINI E, Toffart AC, Perol M, Assie JB, et al
    Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.
    Clin Lung Cancer. 2020 May 8. pii: S1525-7304(20)30136.
    PubMed     Abstract available


  163. KAMIGAICHI A, Tsutani Y, Kagimoto A, Fujiwara M, et al
    Comparing Segmentectomy and Lobectomy for Clinical Stage IA Solid-dominant Lung Cancer Measuring 2.1 to 3 cm.
    Clin Lung Cancer. 2020 May 7. pii: S1525-7304(20)30138.
    PubMed     Abstract available


  164. IJSSELDIJK MA, Shoni M, Siegert C, Wiering B, et al
    Oncologic Outcomes of Surgery Versus SBRT for Non-Small-Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
    Clin Lung Cancer. 2020 May 7. pii: S1525-7304(20)30140.
    PubMed     Abstract available


    April 2020
  165. FRIEDLAENDER A, Liu SV, Passaro A, Metro G, et al
    The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2020 Apr 30. pii: S1525-7304(20)30105.
    PubMed     Abstract available


  166. MORAN T, Taus A, Arriola E, Aguado C, et al
    Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
    Clin Lung Cancer. 2020 Apr 25. pii: S1525-7304(20)30134.
    PubMed     Abstract available


  167. STINCHCOMBE TE, Miksad RA, Gossai A, Griffith SD, et al
    Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression.
    Clin Lung Cancer. 2020 Apr 18. pii: S1525-7304(20)30107.
    PubMed     Abstract available


  168. DE GIGLIO A, Lamberti G, Facchinetti F, Genova C, et al
    Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
    Clin Lung Cancer. 2020 Apr 15. pii: S1525-7304(20)30087.
    PubMed     Abstract available


  169. SHEN E, Xiu J, Bentley R, Lopez GY, et al
    Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma From Other Lung Cancer Histologies.
    Clin Lung Cancer. 2020 Apr 15. pii: S1525-7304(20)30101.
    PubMed     Abstract available


  170. GELATTI ACZ, Cordeiro de Lima VC, Freitas H, Werutsky G, et al
    Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Apr 13. pii: S1525-7304(20)30106.
    PubMed     Abstract available


  171. ABDEL-RAHMAN O
    Incidence and Mortality of Lung Cancer Among Never Smokers in Relationship to Secondhand Smoking: Findings From the PLCO Trial.
    Clin Lung Cancer. 2020 Apr 13. pii: S1525-7304(20)30108.
    PubMed     Abstract available


  172. CATHCART-RAKE EJ, Sangaralingham LR, Henk HJ, Shah ND, et al
    A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer.
    Clin Lung Cancer. 2020 Apr 13. pii: S1525-7304(20)30102.
    PubMed     Abstract available


  173. KIM J, Hyun HJ, Choi EA, Yoo JW, et al
    Diabetes, Metformin, and Lung Cancer: Retrospective Study of the Korean NHIS-HEALS Database.
    Clin Lung Cancer. 2020 Apr 13. pii: S1525-7304(20)30100.
    PubMed     Abstract available


  174. MUKTHINUTHALAPATI VVPK, Putta A, Farooq MZ, Singh SRK, et al
    Knowledge, Attitudes, and Practices Pertaining to Lung Cancer Screening Among Primary Care Physicians in a Public Urban Health Network.
    Clin Lung Cancer. 2020 Apr 11. pii: S1525-7304(20)30083.
    PubMed     Abstract available


  175. SHIRAISHI Y, Kishimoto J, Tanaka K, Sugawara S, et al
    Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Apr 10. pii: S1525-7304(20)30089.
    PubMed     Abstract available


  176. MAYNE NR, Mallipeddi MK, Darling AJ, Jeffrey Yang CF, et al
    Impact of Surveillance After Lobectomy for Lung Cancer on Disease Detection and Survival.
    Clin Lung Cancer. 2020 Apr 10. pii: S1525-7304(20)30099.
    PubMed     Abstract available


    March 2020
  177. CHIAPPETTA M, Leuzzi G, Sperduti I, Bria E, et al
    Mediastinal Up-Staging During Surgery in Non-Small-Cell Lung Cancer: Which Mediastinal Lymph Node Metastasis Patterns Better Predict The Outcome? A Multicenter Analysis.
    Clin Lung Cancer. 2020 Mar 20. pii: S1525-7304(20)30082.
    PubMed     Abstract available


  178. MARTINEZ-MEEHAN D, Lutfi W, Dhupar R, Christie N, et al
    Factors Associated With Survival in Complete Pathologic Response Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2020 Mar 16. pii: S1525-7304(20)30081.
    PubMed     Abstract available


  179. SHUKLA NA, Yan MN, Hanna N
    The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future.
    Clin Lung Cancer. 2020 Mar 12. pii: S1525-7304(20)30075.
    PubMed     Abstract available


  180. MINARI R, Mazzaschi G, Bordi P, Gnetti L, et al
    Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Rea
    Clin Lung Cancer. 2020 Mar 9. pii: S1525-7304(20)30072.
    PubMed     Abstract available


  181. NAIDOO J, Nishino M, Patel SP, Shankar B, et al
    Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Mar 9. pii: S1525-7304(20)30076.
    PubMed     Abstract available


  182. FARRELL MJ, Yahya JB, Degnin C, Chen Y, et al
    Elective Nodal Irradiation for Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Practice Patterns.
    Clin Lung Cancer. 2020 Mar 7. pii: S1525-7304(20)30071.
    PubMed     Abstract available


  183. PRELAJ A, Rebuzzi SE, Pizzutilo P, Bilancia M, et al
    EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.
    Clin Lung Cancer. 2020 Mar 7. pii: S1525-7304(19)30334.
    PubMed     Abstract available


  184. PRELAJ A, Lo Russo G, Proto C, Signorelli D, et al
    DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
    Clin Lung Cancer. 2020 Mar 7. pii: S1525-7304(20)30005.
    PubMed     Abstract available


  185. RAJU S, Khawaja A, Han X, Wang X, et al
    Lung Cancer Screening: Characteristics of Nonparticipants and Potential Screening Barriers.
    Clin Lung Cancer. 2020 Mar 3. pii: S1525-7304(19)30333.
    PubMed     Abstract available


  186. GELSOMINO F, Di Federico A, Filippini DM, Dall'Olio FG, et al
    Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Clin Lung Cancer. 2020;21:e45-e48.
    PubMed    


  187. BARBOSA MVR, Cordeiro de Lima VC, Formiga MN, Andrade de Paula CA, et al
    High Prevalence of EGFR Mutations in Lung Adenocarcinomas From Brazilian Patients Harboring the TP53 p.R337H Variant.
    Clin Lung Cancer. 2020;21:e37-e44.
    PubMed    


  188. MATSUBARA T, Uchi H, Haratake N, Takamori S, et al
    Acute Generalized Exanthematous Pustulosis Caused by the Combination of Pembrolizumab Plus Chemotherapy in a Patient With Squamous-Cell Carcinoma.
    Clin Lung Cancer. 2020;21:e54-e56.
    PubMed    


  189. MAZZASCHI G, Bordi P, Fioretzaki R, Gnetti L, et al
    Nivolumab-Induced Guillain-Barre Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma.
    Clin Lung Cancer. 2020;21:e65-e73.
    PubMed    


  190. TANNER NT, Brasher PB, Jett J, Silvestri GA, et al
    Effect of a Rule-in Biomarker Test on Pulmonary Nodule Management: A Survey of Pulmonologists and Thoracic Surgeons.
    Clin Lung Cancer. 2020;21:e89-e98.
    PubMed     Abstract available


  191. ZHANG Y, Yu M, Yuan M, Chen R, et al
    Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.
    Clin Lung Cancer. 2020;21:e78-e83.
    PubMed    


  192. KINSLOW CJ, May MS, Saqi A, Shu CA, et al
    Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
    Clin Lung Cancer. 2020;21:e99-e113.
    PubMed     Abstract available


  193. ERSEK JL, Symanowski JT, Han Y, Howard A, et al
    Pulmonary Carcinosarcoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
    Clin Lung Cancer. 2020;21:160-170.
    PubMed     Abstract available


    February 2020
  194. MARTIN C, Lupinacci L, Perazzo F, Bas C, et al
    Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.
    Clin Lung Cancer. 2020 Feb 26. pii: S1525-7304(20)30039.
    PubMed     Abstract available


  195. FINK-NEUBOECK N, Lindenmann J, Porubsky C, Fediuk M, et al
    Hazards of Recurrence, Second Primary, or Other Tumor at Ten Years After Surgery for Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2020 Feb 26. pii: S1525-7304(20)30036.
    PubMed     Abstract available


    January 2020
  196. MARMARELIS ME, Langer CJ
    Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.
    Clin Lung Cancer. 2020 Jan 27. pii: S1525-7304(20)30010.
    PubMed     Abstract available


  197. MATTAR MS, Chang J, Benayed R, Halpenny D, et al
    Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.
    Clin Lung Cancer. 2020;21:e25-e29.
    PubMed    


  198. TSUTSUMI H, Yoneshima Y, Ota K, Otsubo K, et al
    Multiclonality and Radiosensitivity of Granulocyte-colony Stimulating Factor-Producing Lung Adenocarcinoma Positive for an Activating EGFR Mutation.
    Clin Lung Cancer. 2020;21:e21-e24.
    PubMed    


  199. FRANCESCHINI D, De Rose F, Cozzi S, Renna I, et al
    Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.
    Clin Lung Cancer. 2020;21:86-93.
    PubMed     Abstract available


  200. DOI H, Kuribayashi K, Kitajima K, Yamakado K, et al
    Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.
    Clin Lung Cancer. 2020;21:66-74.
    PubMed     Abstract available


  201. GUO HY, Lin JT, Huang HH, Gao Y, et al
    Development and Validation of a (18)F-FDG PET/CT-Based Clinical Prediction Model for Estimating Malignancy in Solid Pulmonary Nodules Based on a Population With High Prevalence of Malignancy.
    Clin Lung Cancer. 2020;21:47-55.
    PubMed     Abstract available


  202. CASTELLO A, Toschi L, Rossi S, Finocchiaro G, et al
    Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Clin Lung Cancer. 2020;21:28-36.
    PubMed     Abstract available


    November 2019
  203. JELINEK MJ, Armstrong SA, Patel JD, Subramaniam DS, et al
    Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy.
    Clin Lung Cancer. 2019;20:e597-e600.
    PubMed    


  204. GUISIER F, Piton N, Salaun M, Thiberville L, et al
    ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.
    Clin Lung Cancer. 2019;20:e593-e596.
    PubMed    


  205. MODING EJ, Liang R, Lartey FM, Maxim PG, et al
    Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors.
    Clin Lung Cancer. 2019;20:461-468.
    PubMed     Abstract available


  206. PROTO C, Signorelli D, Mallone S, Prelaj A, et al
    The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
    Clin Lung Cancer. 2019;20:e652-e660.
    PubMed     Abstract available


  207. SCHULZ C, Gandara D, Berardo CG, Rosenthal R, et al
    Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.
    Clin Lung Cancer. 2019;20:451-460.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: